Key facts
- This page summarizes Jennifer Lyn Herron's Form 4 filing for GENOCEA BIOSCIENCES, INC..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Sep 2021, 16:02.
Jennifer Lyn Herron - 09 Sep 2021 Form 4 Insider Report for GENOCEA BIOSCIENCES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 09 Sep 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Sep 2021, 16:02:27 UTC
- Prior SEC filing
- 28 Sep 2021
- Next SEC filing
- 30 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Diantha Duvall, Attorney-in-Fact for Jennifer Herron
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jennifer Lyn Herron filed Form 4 for GENOCEA BIOSCIENCES, INC. on 28 Sep 2021.
Change
- Previous filing in this sequence was filed on 28 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GNCA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 09 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $2.02
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options are scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.